Protagonist Therapeutics, Inc. (PTGX) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Newark, CA, United States. The current CEO is Dinesh V. Patel.
PTGX has IPO date of 2016-08-11, 124 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $6.68B.
Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing peptide-based therapeutic drugs for hematology, blood disorders, and inflammatory and immunomodulatory diseases. The company's clinical pipeline includes rusfertide (PTG-300), an injectable hepcidin mimetic in Phase II trials for polycythemia vera and hereditary hemochromatosis; PN-943, an oral integrin antagonist peptide in Phase II development for inflammatory bowel disease; and PN-235, an orally delivered interleukin-23 receptor antagonist for IBD and other indications. Protagonist maintains a license and collaboration agreement with Janssen Biotech, Inc. and operates from its headquarters in Newark, California.
